Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Carlyle Group Inc.
BioCentury | Apr 1, 2025
Deals
Novo, Merck each pay $200M for pipeline additions: Deals Report
Pharmas enter nine-figure upfront deals in metabolic, cardiovascular areas; plus, Bluebird will consider competing buyout offer
BioCentury | Feb 21, 2025
Deals
With debt looming, Bluebird accepts buyout offer from Carlyle, SK Capital
Incoming CEO Meek would need to drive steep growth in product sales to fulfill highly backloaded deal, with 70% of its value tied up in a CVR
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Aug 22, 2024
Finance
Venture Report: Megarounds for BridgeBio newco, Pathalys and the latest from Versant
$300M raise for rare disease company GondolaBio headlines the week’s biggest venture rounds
BioCentury | Feb 29, 2024
Deals
In Trodelvy pact, Gilead drawing clinical expertise from Abingworth’s Launch team
With important work ahead for ADC in lung cancer, Gilead strikes co-development deal with Carlyle-owned life sciences firm
BioCentury | Oct 30, 2023
Finance
New $356M fund gives Abingworth more cash for late-stage trials
With some biopharmas strapped for cash to fund Phase III programs, PE-backed firm’s co-investment fund now supplements co-development fund
BioCentury | Jun 10, 2022
Finance
Predicting the fallout from private equity’s inroads into biotech
Dynamics include increased growth capital, shifting opportunities in company creation
BioCentury | Apr 11, 2022
Deals
Via Abingworth takeout, Carlyle gains biotech skill set
Ending a 49-year run as an independent firm, Abingworth will gain Carlyle’s resources to invest in expensive co-development programs
Items per page:
1 - 9 of 9